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Abstract 
Hyperoxia-induced injury to the developing lung, impaired alveolarization and dysregulated 
vascularization are critical factors in the pathogenesis of bronchopulmonary dysplasia (BPD); 
however, mechanisms for hyperoxia-induced development of BPD are not fully known. Here we 
show that the triggering receptor expressed on myeloid cells 1 (TREM-1) is upregulated in 
hyperoxia-exposed neonatal mice lungs as well as in TA and lungs of human neonates with 
respiratory distress syndrome (RDS) and BPD as an adaptive response to survival in hyperoxia. 
Inhibition of TREM-1 function using siRNA approach or deletion of TREM-1 gene in mice 
showed enhanced lung inflammation, alveolar damage and mortality of hyperoxia-exposed 
neonatal mice. The treatment of hyperoxia-exposed neonatal mice with agonistic TREM-1 
antibody decreased lung inflammation, improved alveolarization and was associated with 
diminished necroptosis regulating protein receptor-interacting protein kinase 3 (RIPK3). 
Mechanistically, we show that TREM-1 activation alleviates lung inflammation and improves 
alveolarization through down-regulating RIPK3 mediated necroptosis and nucleotide-binding 
oligomerization domain-like receptor containing pyrin domain 3 (NLRP3)-inflammasome 
activation in hyperoxia-exposed neonatal mice. These data show that activating TREM-1, 
enhancing angiopoietin 1 signaling or blocking RIPK3-mediated necroptosis pathway may act as 
new therapeutic interventions to control adverse effects of hyperoxia on the development of BPD.  
Word count for abstract: 196 
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Introduction 
Hyperoxia-induced injury to the developing lung, impaired alveolarization and dysregulated 
vascularization are critical factors in the pathogenesis of BPD (1, 2); however, mechanisms for 
hyperoxia-induced development of BPD are not fully known. Following hyperoxia-induced acute 
lung injury (HALI) or mechanical ventilation during premature birth, damage-associated 
molecular patterns (DAMPs) are released from necrotic cells and recognized by pattern 
recognition receptors (PRRs) that include toll like receptors (TLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors (3-5).  The activation of these molecules has been 
recognized as a modulator of inflammation and decreased alveolarization in a mouse model of 
BPD (3) as well as in preterm infants (3). In recent years, a new family of the innate immune 
receptor has been identified -- known as triggering receptors expressed on myeloid cells (TREMs) 
-- that have been shown to modulate immune response due to their ability to amplify or decrease 
the signals induced by TLRs and NOD-like receptors (6, 7). However, the role of TREM-1 in 
neonatal HALI and contribution to the development of BPD is not known. 
We tested the hypothesis whether TREM-1 expression is required for limiting lung inflammation, 
alveolar injury and survival in hyperoxia.  We report that TREM-1 expression is increased in the 
lungs of hyperoxia-exposed neonatal mice as well as human neonates with respiratory distress 
syndrome (RDS) and BPD as an adaptive survival response. In hyperoxia-exposed neonatal mice, 
we observed that deletion of TREM-1 gene in mice leads to increased lung inflammation, alveolar 
damage and mortality. We further observed that increased lung inflammation is associated with 
enhanced necroptosis regulating protein receptor-interacting protein kinase 3 (RIPK3)-mediated 
necroptosis and nucleotide-binding oligomerization domain-like receptor containing pyrin domain 
3 (NLRP3)-inflammasome activation in the lungs of hyperoxia-exposed neonatal mice and human 
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neonates with RDS and BPD. We next tested whether TREM-1 arbitrates protection to hyperoxia-
exposed neonatal mice by blocking necroptosis regulating protein RIPK3-mediated necroptosis 
and NLRP3-inflammasome activation. The treatment of hyperoxia-exposed neonatal mice with 
agonistic TREM-1 antibody decreased NLRP3-inflammasome activation, improved 
alveolarization and was associated with diminished RIPK3-mediated necroptosis in the lungs of 
neonatal mice. Mechanistically, we show that TREM-1 alleviates pulmonary inflammation and 
alveolar injury by down regulating RIPK3 mediated necroptosis and NLRP3-inflammasome 
activation through induction of vascular endothelial growth factor-A (VEGF-A) and augmenting 
angiopoietin1 (Ang1) expression in lung of hyperoxia-exposed neonatal mice. Taken together, our 
data show that activating TREM-1, enhancing Ang1 signaling or blocking RIPK3 mediated 
necroptosis may represent novel therapeutic targets for HALI and BPD in neonates. 
 
Results 
Hyperoxia induces TREM-1 expression localized to alveolar macrophages in neonatal mice 
lungs 
To determine the contribution of TREM-1 to HALI, we first examined the expression of TREM-
1 and its localization in the lung compartments of room air (RA; 21% O2) or hyperoxia (60% O2) 
exposed neonatal mice. We selected 60% O2, as opposed to 80-100% O2, to more closely mimic 
the supplemental O2 exposure as currently used for human neonates, predisposing them to 
developing the more common moderate BPD versus the severe BPD phenotype (8). As shown in 
Figs. 1A and 1B, the transcript and protein expression of TREM-1 were significantly higher in the 
lungs of hyperoxia-exposed neonatal mice compared to RA littermates at postnatal day (PN) 7. To 
evaluate the constitutive presence of TREM-1 within the pulmonary compartment, cells from 
bronchoalveolar lavage fluid (BALF) and lungs were collected from RA or hyperoxia-exposed 
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neonatal mice at PN7 for flow cytometric or confocal microscopic analysis, respectively. As shown 
in Supplementary Figs. 1A and 1B, the expression of TREM-1 on alveolar macrophages (AM; 
CD11c positive cells) was higher in cells isolated from BALF as well as in lung tissue of 
hyperoxia-exposed neonatal mice compared to RA group.  
To further confirm the induction and localization of TREM-1 by AM, we isolated AM from BALF 
of RA and hyperoxia-exposed neonatal mice at PN7 and measured transcript and protein 
expression of TREM-1 levels. As shown in Figs. 1C and 1D, the transcript and protein expression 
of TREM-1 were significantly higher in AM isolated from neonatal mice exposed to hyperoxia 
compared to RA group.  To corroborate these in vivo findings, we exposed murine macrophage-
like RAW 264.7 cells to RA or hyperoxia for various time points and measured the transcript and 
protein levels of TREM-1. As shown in Figs. 1E and F, transcript levels of TREM-1 were elevated 
in a time-dependent manner in murine macrophage-like RAW 264.7 cells exposed to hyperoxia. 
Taken together, these results suggest that TREM-1 expression is enhanced in response to 
hyperoxia and is localized to AM in the developing lung. 
TREM-1 expression is up-regulated in human neonatal lungs with RDS and BPD 
To ascertain the relevant potential functional role of TREM-1 in the development of BPD, we 
assessed the relative expression of TREM-1 in the tracheal aspirates (TA) and lung tissues of 
human neonates with RDS and BPD. We found that the transcript level of TREM-1 was 
significantly higher in the TA of infants who subsequently developed BPD/died compared to those 
who did not develop BPD (Fig. 1G). The detailed characterizations of enrolled infants are shown 
in Supplementary Table 1. We next measured TREM-1 protein level in the lungs of human 
neonates at various stages of BPD development. We found that the protein level of TREM-1 was 
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significantly higher in lungs of neonates with RDS and BPD compared to term control babies (Fig. 
1H). The detailed characterizations of this 2nd independent cohort of enrolled infants are shown 
in Supplementary Table 2. Finally, we confirmed the increased level of TREM-1 in lungs of 
neonates with RDS and BPD by immunohistochemical staining in a 3rd independent cohort of 
human neonatal lungs with RDS and BPD (Fig. 1I). The detailed characterization of enrolled 
infants is shown in Supplementary Table 3. Altogether, these data from experimental hyperoxia-
exposed neonatal mice and three independent cohorts of human lung samples from RDS and BPD 
neonates confirmed that TREM-1 is induced during hyperoxia exposure in the developing lung.  
Suppression or deletion of TREM-1 gene is associated with increased pulmonary alveolar 
injury and mortality  
To evaluate the functional role of TREM-1 on the outcome of pulmonary alveolar injury and 
mortality in hyperoxia-exposed neonatal mice, we first studied loss-of-function of TREM-1 using 
a siRNA approach to inhibit TREM-1 function or completely abolish TREM-1 function using 
TREM-1/3- deficient mice. We selected TREM-1/3 deficient mice because previous studies have 
shown that TREM-1 lies adjacent to TREM-3 gene and that these 2 genes are likely to have 
complementary functions (9). Additionally, TREM-3 is a pseudogene in humans; hence, TREM-
1/3 deficient mice would reflect the lack of functionality of TREM-1 in humans (9). As shown in 
Fig. 2A, TREM-1 transcript levels were significantly decreased (75%) in the lungs of neonates 
treated with TREM-1-siRNA compared with the scrambled siRNA (scr-siRNA) treated group. We 
next determined the effect of TREM-1 silencing on hyperoxia-exposed neonatal mice. 
Surprisingly, we found that inhibition of TREM-1 led to enhanced lung inflammation as 
manifested by increased neutrophil recruitment (Fig. 2B) and inflammatory cytokine interleukin 
(IL)-1β (Fig. 2C) in the lungs of neonatal mice exposed to hyperoxia. This increased lung 
inflammation was also allied with impaired alveolarization as demonstrated by increased chord 
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length (Figs. 2D and 2E) and decreased radial alveolar count (Fig. 2F) in the lungs of TREM-1-
siRNA mice exposed to hyperoxia. These detrimental effects of TREM-1 inhibition were 
concomitant with decreased vascularization (Fig. 2G), increased apoptosis (Fig. 2H) and higher 
mortality of hyperoxia-exposed TREM-1-siRNA neonatal mice, as compared to the scr-siRNA 
mice group (Supplementary Fig. 2).  
To finally confirm the loss-of-function of TREM-1 in pulmonary inflammation and alveolar 
damage and the survival response to hyperoxia, we challenged newborn TREM-1/3–deficient and 
control WT mice to hyperoxia or RA till PN7. Similar to the results of TREM-1-siRNA treated 
mice exposed to hyperoxia, we found that TREM-1/3-deficient neonatal mice also showed 
enhanced neutrophil recruitment (Fig. 2I) and myeloperoxidase levels (Fig. 2J) in the lungs.  In 
addition, we noted robust lung inflammation as manifested by increased inflammatory cytokines 
IL-6 and IL-1β (Figs. 2K and L), increased alveolar damage as demonstrated by enhanced chord 
length, decreased radial alveolar count (Figs. 2M-O) and increased mortality in hyperoxia-exposed 
TREM-1/3-deficient neonatal mice (Fig. 2P). Importantly, we did not detect any changes in lung 
morphometry, inflammation and mortality in TREM-1/3-deficient neonatal mice exposed to RA 
as compared to wild type (WT) littermates. These results suggest that enhanced TREM-1 
expression may be essential for protecting developing lung against hyperoxia-induced lung 
inflammation, alveolar injury and survival during hyperoxia. 
 
TREM-1 activation decreases lung inflammation and alveolar injury in hyperoxia-exposed 
neonatal mice 
Because we found the inhibition of TREM-1 expression in lungs led to increased lung 
inflammation, alveolar injury and mortality in hyperoxia-exposed neonatal mice, we reasoned that 
augmenting pulmonary TREM-1 expression would attenuate pulmonary alveolar injury and 
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improve survival. To test this hypothesis, we treated hyperoxia or RA exposed neonatal mice with 
the TREM-1 agonist antibody on alternate days starting at postnatal (PN) day 2 through PN6. The 
control group was treated similarly with an isotype antibody. Consistent with the known agonistic 
activity of TREM-1 antibody (10, 11), we found that augmentation of TREM-1 in hyperoxia-
exposed neonatal mice led to decreased neutrophil recruitment (Fig. 3A)  and myeloperoxidase 
levels (Fig. 3B) and reduced lung inflammation as demonstrated by decreased levels of pro-
inflammatory cytokines IL-6 and IL-1β in the lungs. (Figs. 3C and D), and improved 
alveolarization as manifested by decreased chord length and increased radial alveolar count (Figs. 
3E-G). Furthermore, these improvements in lung alveolarization was also accompanied with 
decreased staining of 8-Oxo-2’-deoxyguanosine in the lung (8-oxo-dG) (Supplementary Fig. 3). 
Notably, we did not detect any changes in lung morphometry and inflammation in RA groups of 
neonatal mice treated with TREM-1 agonist or isotype antibodies. Collectively, these results 
suggest that stimulating TREM-1 activation using the TREM-1 agonist antibody protects against 
HALI through reduction of lung inflammation.  
Previously, TREM-1 has been shown to be crucial for modulating macrophage polarization (12, 
13). We reasoned that TREM-1 activation may also polarize macrophages to the M2 phenotype to 
result in a protective response in the lung during hyperoxia. Consistent with this hypothesis, we 
found that TREM-1 activation polarizes macrophages to the M2 phenotype as manifested by 
increased levels of M2 markers (Ym1, KLF4 and Arginine 1) and decreased expression of M1 
markers (inducible nitric oxide synthase or iNOS, IL-6 and Ccl2) in whole lungs and AM (Figs. 
3H-K). These data suggest that TREM-1 activation is required to resolve lung inflammation and 
injury during hyperoxia exposure to the developing lung.  
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Increased NLRP3-inflammasome activation is associated with increased lung necroptosis in 
human neonates with RDS and BPD  
Recently, it has been reported that NLRP3-inflammasome, a key mediator of inflammation, is 
activated in the lungs of neonatal mice (3) and rat (14) exposed to hyperoxia and in the TA of 
preterm infants with respiratory failure (3). Consistent with their findings, we now detected an 
increased expression of NLRP3-inflammasome markers -- NLRP3, Caspase-1 and IL-1β -- in 
human neonatal lungs at various stages of BPD development (Fig. 4A) and in the lungs of neonatal 
mice exposed to hyperoxia (Supplementary Fig. 4). These results further strengthen the 
involvement of NLRP3-inflammasomal activation in the development of BPD; however, the 
mechanism(s) for NLRP3-inflammasome activation are not known.  
We have previously shown that the high-mobility group box-1 (HMGB1) protein, which 
is released from necrotic cells, is higher in TA from premature infants who develop BPD (15) and 
now we have confirmed our earlier result with the increased HMGB1 levels in the lungs of human 
infants developing BPD (Fig. 4B). These finding suggest that lung necroptosis may have a crucial 
role in the development of BPD. Necroptosis, a form of programmed necrotic cell death, amplifies 
NLRP3-inflammasome activation (16, 17) and has been shown to play a critical role in lung 
diseases such as adult RDS (ARDS) (4, 18-20), chronic obstructive pulmonary disease (COPD) 
(21) and sepsis (22, 23). We reasoned that increased NLRP3-inflammasome activation might also 
be functionally related to increased necroptosis in lungs of human infants developing BPD and 
neonatal mice exposed to hyperoxia. To test this possibility, we first verified the expression and 
activation of RIPK3, a regulator protein in the necroptosis pathway in human lungs of neonates 
with RDS and BPD and in the lungs of neonatal mice exposed to hyperoxia. As shown in Fig. 4B, 
phosphorylation of RIPK3 was significantly increased in human neonatal lungs at various stages 
of BPD development. Consistent with increased RIPK3 activation in human neonatal lungs at 
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various stages of BPD, neonatal mice exposed to hyperoxia also showed increased activation of 
RIPK3 in the lungs (Supplementary Fig. 5).  
To further explore the involvement of RIPK3 mediated necroptosis, we measured mixed lineage 
kinase like (MLKL), a downstream substrate of RIPK3 which is necessary for RIPK3 kinase 
activity to execute necroptosis (3, 16). We found increased phosphorylation of MLKL in the lungs 
of human infants with RDS and BPD (Fig. 4B), and in the lungs of neonatal mice exposed to 
hyperoxia (Supplementary Fig. 5). Collectively, these results from human infants with RDS/BPD 
and hyperoxia-exposed neonatal mice suggests that lung necroptosis during hyperoxia may be 
involved in the activation of NLRP3-inflammasome in the neonatal lung.  
Inhibition or deletion of RIPK3 reduces necroptosis and NLRP3-inflammasome activation 
Next, we examined the functional relationship between RIPK3 mediated necroptosis and NLRP3-
inflammasome activation using pharmacological or molecular approaches. We repressed RIPK3 
activity using the RIPK3 inhibitor GW440139B (0.5µM) (also known as GW’39B) which disrupts 
RIPK3-MKLKL complex and inhibits necroptosis (24) and also utilized RIPK3 specific null 
mutant mice to confirm the role of RIPK3 mediated necroptosis in NLRP3-inflammasome 
activation. We found that RIPK3 inhibitor GW’39B significantly decreased phosphorylation of 
MLKL which is required for executing necroptosis (Fig. 5A). This decreased lung necroptosis was 
also associated with diminished NLRP3-inflammasome activation as manifested by decreased 
NLRP3, activated caspase-1 and IL-1β expression in lungs of hyperoxia-exposed neonatal mice 
(Fig. 5B) suggesting that necroptotic cell death during hyperoxia mediates NLRP3-inflammasome 
activation in the lung. We next examined whether inhibition of RIPK3 also ameliorated pulmonary 
inflammation and alveolar injury in hyperoxia-exposed neonatal mice. As shown in Figs. 5C-F, 
RIPK3 inhibition attenuated lung inflammation, as measured by decreased neutrophil recruitment, 
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myeloperoxidase and levels of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, IL-6 
and IL-1 in the lungs. This reduction in lung inflammation was associated with a marked 
reduction in pulmonary alveolar injury as manifested by improved alveolarization (decreased 
chord length and increased radial alveolar count), compared to hyperoxia group not receiving any 
treatment (Figs. 5G and H and Supplementary Fig. 6).  
Similar to the results of RIPK3 inhibitor GW’39B, the RIPK3 null mutant mice also showed robust 
protection against hyperoxia-induced acute lung inflammation and alveolar injury by reducing 
lung necroptosis and NLRP3-inflammasome activation (Figs. 5I-R). Altogether, these findings 
indicate that suppression of RIPK3 expression by a RIPK3 inhibitor or genetic deletion of RIPK3 
reduces lung inflammation and attenuates pulmonary alveolar damage in hyperoxia-exposed 
neonatal mice through inhibition of NLRP3-inflammasome activation.  
TREM-1 deletion is associated with increased lung necroptosis and NLRP3-inflammasome 
activation  
Because we found that TREM-1 inhibition induced lung inflammation in hyperoxia-exposed 
neonatal mice, we reasoned that TREM-1 may be involved in lung necroptosis and NLRP3-
inflammasome activation. To test this hypothesis, we examined the markers for RIPK3-mediated 
necroptosis and NLRP3-inflammasome activation in TREM-1/3- deficient mice exposed to 
hyperoxia and compared to WT littermates. As shown in Fig. 6A, activated forms of RIPK3 and 
its downstream substrate phosphorylation of MLKL is increased in the lungs of TREM-1/3- 
deficient neonatal mice exposed to hyperoxia as compared to WT neonatal mice. This increased 
RIPK3-mediated necroptosis is also associated with increased NLRP3-inflammasome activation 
in TREM-1/3- deficient neonatal mice (Fig. 6B) suggesting that TREM-1 may be involved in the 
regulation of RIPK3 mediated lung necroptosis during hyperoxia exposure to neonates.  
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TREM-1 activation suppresses RIPK3 mediated necroptosis through induction of 
angiopoietin 1 expression 
Finally, to address whether diminution of lung inflammation and alveolar injury by TREM-1 
activation is arbitrated through the suppression of RIPK3 mediated necroptosis, we treated 
hyperoxia-exposed neonatal mice with the TREM-1 agonist antibody and measured HMGB1, 
RIPK3 and its downstream protein MLKL. We found that TREM-1 agonist antibody reduced 
HMGB1 expression and RIPK3 mediated necroptosis as manifested by decreased expression of 
RIPK3 and its downstream protein MLKL phosphorylation in the whole lung as well as 
macrophages isolated at PN7 and exposed to hyperoxia in culture (Figs. 7A-D). This decrease in 
lung necroptosis is also associated with significant decrease NLRP3-inflammasome activation as 
demonstrated by diminished expression of inflammasome markers; NLRP3, active caspase 1 and 
IL-1β in the lungs of neonatal mice treated with TREM-1 agonist antibody (Fig. 7B).  
Given the fact that TREM-1 is also found in endothelial cells, we decided to investigate if there 
was a role for angiogenic agents in this pathway.  We found that decreased lung necroptosis was 
also associated with increased expression of angiopoietin 1 (Ang1) and decreased expression of 
Ang2 proteins (Figs. 7C and D) suggesting that TREM-1 may show attenuation of necroptosis 
through activation of Ang1.  
To investigate whether Ang1 expression is directly involved in the repression of RIPK3 activity, 
we treated TREM-1/3-deficient mice with recombinant Ang1 during hyperoxia and measured 
RIPK3-mediated necroptosis and Ang protein expression in the lung. As expected, we found that 
administration of recombinant Ang1 caused significantly increased Ang1 protein levels, enhanced 
expressions of vascular endothelial growth factor (VEGF)-A, Tie-2 (receptor for Ang1 and 2) and 
decreased level of Ang2 in the lungs of TREM-1/3-deficient mice (Fig. 8A). These changes in 
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angiopoietin protein expression were associated with decreased expression of RIPK3 and its 
downstream substrates MLKL activation in the lungs of TREM-1/3-deficient mice (Fig. 8B). We, 
and others, have previously shown that increased Ang2, an antagonist of Ang1, caused necrosis 
upon hyperoxia exposure in developing and adult mice lungs (25, 26). Taken together, our results 
suggest that TREM-1 may, in part, regulate RIPK3 mediated necroptosis through the VEGF-A 
mediated Ang1/2 signaling pathway in HALI (Fig. 8C).  
 
Discussion 
TREM-1 has been reported as an amplifier of the inflammatory response to bacterial infection and 
sepsis (7, 27, 28). Several previous studies have shown that treatment with TREM-1 inhibitors can 
act as a therapeutic strategy to prevent excessive systemic inflammation resulting in decreased 
severity of sepsis (27, 28) and mortality (12, 29). In contrast, other studies have recognized TREM-
1 as a survival factor for the host against bacterial infection and sepsis (9). For example, it has 
been demonstrated that deletion of TREM-1/3- gene in mice leads to increased local as well as 
systemic cytokine production and enhanced mortality during polymicrobial induced sepsis (29, 
30). These results suggest that TREM-1 has a sundry role in inflammation and infection and further 
investigation is required to explore the functional role of TREM-1 in various diseases.  Here, we 
explored a new role of TREM-1 in hyperoxia-induced pulmonary alveolar injury and its 
consequence in the development of BPD. We demonstrated, for the first time, that TREM-1 
expression is increased in the lungs of neonatal mice and human neonates with RDS and BPD in 
hyperoxia as an adaptive response to protect the lung from oxygen and/or ventilation-induced 
injury. This is evident from our finding that silencing TREM-1 expression in lungs or genetic 
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deletion of TREM-1 in mice showed increased pulmonary alveolar injury and mortality when 
exposed to hyperoxia. Further, we observed that augmentation of TREM-1 expression in neonatal 
lungs reduces inflammation and pulmonary alveolar injury and is associated with decreased 
NLRP3-inflammasome activation and RIPK3-mediated necroptosis.  
Previously it has been reported that TREM-1/3-deficient adult mice infected with Pseudomonas 
aeruginosa showed a markedly increased mortality; however, they found a decreased neutrophil 
recruitment to the lungs following Pseudomonas aeruginosa challenge (9). We report here that 
TREM-1/3-deficient neonatal mice have increased neutrophil recruitment during hyperoxia. This 
discrepancy in results may be due to differential stage of lung development / age of mice (neonate 
vs adult) and/or mode of injury (hyperoxia vs bacterial infection) that we used in our study.  
RIPK3-mediated necroptosis has been identified in several lung diseases such as ARDS (4, 18-
20), COPD (21), and sepsis (22, 23). We now add neonatal HALI and BPD to this list and identify 
TREM-1, Ang1, and RIPK3 as potential therapeutic targets for the treatment of these life-
threatening disorders. Here, we reveal that necroptosis regulating protein RIPK3 and its 
downstream substrate MLKL levels were higher in the lungs of human infants with RDS, evolving 
BPD and established BPD as well as in lungs of neonatal mice exposed to hyperoxia, suggesting 
the essential role of necroptosis in HALI and the development of BPD. Further, using both genetic 
and drug-based approaches, we revealed a decisive role of RIPK3 in HALI in neonatal mice. Our 
mechanistic data showed that RIPK3 inhibitor GW440139B or RIPK3-deficient neonatal mice 
exposed to hyperoxia showed decreased phosphorylation of MLKL and diminished necroptosis 
and NLRP3-inflammasome activation in the lung. These findings are similar to the recent studies 
of Wang et al (20) and Mizumura et al (21), who showed that RIPK3-mediated necroptosis is a 
major mechanism for lung inflammation and injury in experimental models of ARDS and COPD.  
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Another important finding of this study is that we illustrated for the first time that the inflammation 
mediator NLRP3-inflammasome is regulated by RIPK3 mediated necroptosis in HALI in neonatal 
mice. Recently, NLRP3-inflammasome has been shown to be activated in neonatal mice exposed 
to hyperoxia (85% oxygen) and in a preterm baboon model of BPD (24). The blocking of NLRP3-
inflammasome resulted in decreased lung inflammation and improved pulmonary alveolarization; 
however, the mechanism for NLRP3-inflammasome activation during hyperoxia has not been 
explored. We showed that NLRP3-inflammasome activation may be due to increased necroptosis 
during hyperoxia in neonatal mice. This is supported by our finding that RIPK3 inhibitor 
GW440139B and genetic deletion of RIPK3 in mice is related to decreased NLRP3-inflammasome 
activation, caspase-1 and IL-1β in neonatal mice exposed to hyperoxia. These results are further 
supported by several earlier studies showed that multiple DAMPs (HMGB1, histones, mtDNAs) 
released by necroptotic cells triggered sustained cytokine release and amplified the inflammatory 
response in diseases (15, 31-33). Consistent with this line of evidence, we have also previously 
shown increased levels of HMGB1 in the TA of infants who developed BPD (15)  and now we 
show that there is an increase in HMGB1 and caspase 8 expression in the lungs of human infants 
with BPD as well as neonatal mice exposed to hyperoxia. Collectively, these data suggest that the 
activation of NLRP3-inflammasome may be due to increased necroptosis in the lungs of infants 
exposed to invasive ventilation/hyperoxia which leads to the development of BPD.  
Lastly, we demonstrate that the protection conferred by augmenting TREM-1 expression strongly 
suppressed the activity of RIPK3 and decreased the phosphorylation of its downstream substrate 
MLKL which is required to execute necroptosis (34, 35).  While TREM-1 has been known to be a 
pro- as well as anti-inflammatory molecule that has contributed to its ability to exacerbate or 
mitigate inflammation in the lung respectively, we explored a new function of TREM-1 which 
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confers protection in the hyperoxia-exposed neonatal mice through induction of Ang1 and 
suppression of Ang2 in the neonatal mice treated with TREM-1 agonist antibody. We have 
previously reported that Ang2 increases inflammation and necroptotic cell death during hyperoxia 
in mice (25, 26). These findings, along with the results from the current study indicate that TREM-
1 is a functionally important protein in the neonatal lung for improved alveolarization and survival 
in hyperoxia. In the future, it will be important to clarify the precise mechanism by which TREM-
1 regulates Ang1/Ang2 signaling in HALI and BPD in neonatal mice. In summary, our results 
strongly suggest that RIPK-dependent necrosis is the common denominator between TREM-1 
signaling and development of BPD as a consequence of HALI in neonatal mice.  
Methods 
Human lung TA  
Human lung TA pellets were obtained from premature infants being mechanically ventilated in the 
first PN week with an in-dwelling endotracheal tube. These infants had the final outcomes of 
having the diagnoses of with or without BPD and/or death. The collection and processing of the 
lung TA was approved by the Human Investigation Committee (institutional review board) of Yale 
University (VB). Selected clinical details have been shown in Supplementary Table 1.  
Immunohistochemistry in human neonatal lungs 
Human lung tissue samples were obtained postmortem from premature infants having the 
diagnoses of RDS: 1-2 days (RDS 1-2), RDS 3-7 days (RDS 3-7), RDS >7 days (RDS >7), BPD 
and term infants as controls. Collection and processing of the human lung samples were approved 
by the National Supervisory Authority for Welfare and Health in Finland and the University of 
Rochester Institutional Review Board. Selected clinical details have been shown in 
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Supplementary Tables 2-3. Whole lungs from humans were isolated and immediately fixed with 
10% neutral-buffered formalin. Sections were stained with antibodies against TREM-1 (R&D 
Systems, MN). TREM-1 staining was quantified by randomly selecting 5 high-power fields in 
each slide, counting 200 cells in each area, and expressing the number of TREM-1 positive cells 
as a percentage.  
Animals  
All experimental WT mice breeding pairs of the C57BL/6J strain were purchased from The 
Jackson Laboratory (Bar Harbor, ME) while breeding pairs of mice with targeted deletion of 
TREM-1/3 and RIPK3 genes on a C57BL/6J background were obtained from Genentech, San 
Francisco, CA, USA. These null mutant mice have been characterized previously (9, 36). All mice 
were housed and bred in Drexel University animal care facilities and allowed free access to 
standard food and water. All animal protocols were reviewed and approved by the Institutional 
Animal Care and Use Committees of Drexel University prior to performing any studies.  
Neonatal mouse model of HALI 
Newborn (NB) mice were used in all studies and litter sizes for each experiment were adjusted to 
8-10 pups per treatment group to minimize the effects of differences in nutrition on lung 
development. For the HALI model, NB WT, TREM-1/3-/- and RIPK3-/- mice were exposed to 
either RA (21% O2) or hyperoxia (60% O2) continuously from PN1 to PN7, as previously described 
(37). Oxygen levels were constantly monitored inside the chamber and mice were exposed to a 
12h light-dark cycle. Nursing mothers were rotated between RA and oxygen-exposed litters daily 
so as to prevent oxygen toxicity and to ensure sufficient nutrition (milk) for indicated time points. 
Both male and female pups were pooled together for various analyses.   
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In separate treatment studies, newborn WT mice were kept in either RA or 60% O2 and injected 
with the TREM-1 agonist antibody (1µg/mouse; R&D catalog number MAB1187) or isotype 
antibody (1µg/mouse; R&D catalog number MAB006) subcutaneously every other day from PN2-
7. The mice were monitored twice a day for clinical signs till the experimental end point. The dose 
of the TREM-1 agonist and isotype antibodies used were based on published literature in mouse 
models of sepsis (10, 11) and optimized in our study. In the studies to inhibit necroptosis in the 
lung, NB WT mice were treated with RIPK3 inhibitor GW440139B (GSK 872, 0.5µM) or vehicle 
alone subcutaneously every other day from PN2-7. The dose of GSK 872 was based on published 
studies (24).  
Analysis of BALF 
BAL was performed, as described previously (38). In brief, lungs were lavaged with 0.2 ml of PBS 
three times and recovered fluid was combined and used to determine the total cell count with TC20 
automated cell counter (Bio-Rad Laboratories) while differential counts were performed on cells 
cyto-centrifuged onto glass slides and stained with Hema3 fixative solution (Fisher Scientific), as 
described previously (39). For some experiments, the isolated cells pellets from BALF was used 
to determine TREM-1 positive cells on alveolar macrophage by flow cytometry using CD11c 
specific antibodies for alveolar macrophage and TREM-1 surface expression as described 
previously (40, 41).  
AM preparation from BALF 
To determine the transcript and protein expression of TREM-1 on AM exposed to hyperoxia, we 
isolated pure AM from BALF of neonatal mice. BALFs were collected, and total cells were 
counted with TC20 automated cell counter as described above. The cells were adjusted to 5 × 
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105/ml using alveolar macrophage medium and incubated in 6 wells tissue culture dishes for 1h. 
The nonadherent cells were discarded and adherent cells were washed twice prior to culture in 
60% O2 condition at 37˚C, 5% CO2 in hyperoxia chamber. The adherent cells were scraped off 
with a sterile cell scraper and differential staining with Hema3 fixative solution (Fisher Scientific) 
revealed ˃ 99% pure alveolar macrophages. These cells were stored in RNA-later for RNA 
isolation for gene transcript analysis and in cell lysis buffer for western blot analysis.  
Cell Culture and Reagents 
Murine macrophage–like RAW 264.7 cells (TIB-71; American Type Culture Collection, 
Manassas, VA) were cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY) 
supplemented with 10% FBS (HyClone™, Gibco), 1% penicillin, and 1% streptomycin (Life 
Technologies, Grand Island, NY) at 37°C in 5% CO2 till 70–80% confluent.  Hyperoxia exposure 
was performed in sealed, humidified chambers flushed with 85% O2/5% CO2 at 37°C, as 
previously described (37). After experimental time points, cells were scraped off with a sterile cell 
scraper and stored in RNA-later for RNA isolation and cell lysis buffer for western blot analysis.  
Enzyme-linked immunosorbent assay 
Cytokines [TNF-α, IL-6, and IL-1β)] and lung myeloperoxidase levels were quantified using 
commercially available DuoSet ELISA kits (R&D Systems) according to the manufacturer’s 
instructions, as previously described (39). 
Western blot analysis 
Western blot analysis was performed as described previously (42). In brief, lung tissues (human 
and neonatal mice) and whole cell extracts were homogenized in RIPA buffer containing protease 
and phosphatase inhibitors (Roche Complete mini). Lung homogenate and cell lysate were 
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centrifuged (14,000 × g) at 4 °C for 15 min and the supernatant was collected for further analysis. 
Thirty micrograms of proteins were loaded onto each well, separated on 10% SDS-polyacrylamide 
gel and then transferred onto a nitrocellulose membrane (Bio-Rad) using a Bio-Rad Mini-Blot 
transfer apparatus. Immunoblotting was performed at 4 °C overnight using primary antibodies 
directed against TREM-1 (R&D Systems, MN), Angiopoietin1 (R&D Systems, MN), 
Angiopoietin2 (R&D Systems, MN), RIPK3 (Cell Signaling, Danvers, MA), p-RIPK3 (Cell 
Signaling, Danvers, MA), Ym1 (Stem Cell Technologies, Vancouver, Canada), Arg1 (BD, San 
Jose CA), iNOS (Santacruz, CA), KLF4 (Cell Signaling, Danvers, MA), p-MLKL (Abcam, 
Cambridge, MA), MLKL (Abcam, Cambridge, MA), HMGB1 (Cell Signaling, Danvers, MA), 
Caspase-8 (Cell Signaling, Danvers, MA), Caspase-1 (Cell Signaling, Danvers, MA), cleaved 
Caspase-3 (Cell Signaling, Danvers, MA), NLRP3 (Cell Signaling, Danvers, MA), IL-1β (Cell 
Signaling, Danvers, MA), GAPDH (Cell Signaling, Danvers, MA), Tubulin (Cell Signaling, 
Danvers, MA) and β-actin (Cell Signaling, Danvers, MA). Membranes were then incubated with 
a 1:5000 dilution of a secondary antibody (Li-Cor Biosciences, Lincoln, NE) at room temperature 
for 1 hr. Protein bands were visualized using the Odyssey infrared imaging system (Li-Cor 
Biosciences, Lincoln, NE).   
Lung Morphometric analysis 
At PN7, 6-7 random images per lung and six lungs per experimental group were characterized for 
measuring lung morphometric analysis. Alveolar size was estimated from the mean chord length 
of the airspace and radial alveolar count (RAC), as described previously (37). Briefly, 
hematoxylin-eosin sections images were analyzed using research-based digital image analysis 
software (Image Pro-Plus 4.0; Media Cybernetics, Silver Spring, MD) and a custom macro written 
for automated investigations of alveolar morphology.  
21 
 
Intranasal delivery of TREM-1 siRNA  
TREM1 siRNA was procured from Ambion and reconstituted to 20µM, following manufacturer’s 
instructions. Briefly, pups were exposed to 60% oxygen immediately after birth following the 
protocol, as described in Sun et al (43). Three microliter of siRNA (20µM) was administered 
intranasally to each nostril, on PN2 and PN4, while undergoing hyperoxia exposure. Scr-siRNA 
(Ambion) was used as control in siRNA experiments. 
RNA extraction and PCR  
Total RNA was isolated from lung using RNeasy® Mini Kit (Cat. 74106, Qiagen Inc., CA, USA) 
and cDNA was synthesized from 1 µg of total RNA using iScript™ reverse transcription (Bio-
Rad) kit. Relative quantitative RT-PCR was performed using TaqMan RT-PCR Master Mix (Bio-
Rad Laboratories) in an iCycler thermocycler (Bio-Rad Laboratories). Primers used were: mouse 
TREM-1, forward 5′-GAGCTTGAAGGATGAGGAAGGC-3′ and reverse 5′-
CAGAGTCTGTCACTTGAAGGTCAGTC-3, mouse IL-6, forward 5’-
CCTTCCAGGATGAGGACATGA -3’ and reverse 5’-TGAGTCACAGAGGATGGGCTC -3’, 
mouse Ccl2, forward 5’-GTTGGCTCAGCCAGATGCA-3’ and reverse 5’- 
AGCCTACTCATTGGGATCATCTTG-3’, mouse β-actin, forward 5′-
TGGAATCCTGTGGCATCCATGAAAC-3′ and reverse 5′-
TAAAACGCAGCTCAGTAACAGTCCG-3′. -actin mRNA expression was used for 
normalization. Real-time PCR was accomplished in triplicate. 
Statistical Analysis 
Statistics were performed using GraphPad Prism 7.0 software. Two-group comparisons were 
analyzed by unpaired Student's t test and multiple-group comparisons were performed using one-
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way analysis of variance (ANOVA) followed by Tukey post hoc analysis. Statistical significance 
was achieved with p < 0.05.  
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